Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.

PLoS One 2013 26;8(6):e67160. Epub 2013 Jun 26.

Hepato-Metabolic Disease Unit and Liver Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Atypical fibroblast growth factors (FGF) 21 and 19 play a central role in energy metabolism through the mediation of Klotho coreceptor. Contradictory findings are available about the association of FGF21 and FGF19 with nonalcoholic fatty liver disease (NAFLD) in humans. We investigated the association of serum FGF21, FGF19 and liver Klotho coreceptor with non-alcoholic steatohepatitis (NASH) and fibrosis in children with NAFLD. Serum FGF21 and FGF19 were measured in 84 children with biopsy-proven NAFLD and 23 controls (CTRL). The hepatic expression of Klotho coreceptor was measured in 7 CTRL, 9 patients with NASH (NASH+) and 11 patients without NASH (NASH-). FGF21 and FGF19 showed a tendency to decrease from CTRL (median FGF21 = 196 pg/mL; median FGF19 = 201 pg/mL) to NASH- (FGF21 = 89 pg/mL; FGF19 = 81 pg/mL) to NASH+ patients (FGF21 = 54 pg/mL; FGF19 = 41 pg/mL) (p<0.001 for all comparisons) and were inversely associated with the probability of NASH and fibrosis in children with NAFLD. The hepatic expression of Klotho coreceptor was inversely associated with NASH (R(2) = 0.87, p<0.0001) and directly associated with serum FGF21 (R(2) = 0.57, p<0.0001) and FGF19 (R(2) = 0.67, p<0.0001). In conclusion, serum FGF19 and FGF21 and hepatic Klotho expression are inversely associated with hepatic damage in children with NAFLD and these findings may have important implications for understanding the mechanisms of NAFLD progression.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0067160PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694051PMC
October 2017
23 Reads

Publication Analysis

Top Keywords

fgf21 fgf19
16
klotho coreceptor
12
serum fgf21
8
nonalcoholic fatty
8
liver disease
8
fatty liver
8
fibroblast growth
8
growth factors
8
patients nash
8
association serum
8
atypical fibroblast
8
nash+ patients
8
pg/ml
6
coreceptor measured
4
nafld controls
4
controls ctrl
4
measured ctrl
4
expression klotho
4
ctrl hepatic
4
hepatic expression
4

References

(Supplied by CrossRef)
Pathology of nonalcoholic fatty liver disease
EM Brunt et al.
Nat Rev Gastroenterol Hepatol 2010
Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk
L Pacifico et al.
World J Gastroenterol 2011
Nonalcoholic fatty liver disease in children
A Alisi et al.
Curr Opin Clin Nutr Metab Care 2010
Physiology of FGF15/19
SA Jones et al.
Adv Exp Med Biol 2012

Similar Publications